If you are considering filing a San Francisco Onglyza lawsuit, then Class Action Coalition Lawyers is more than happy to offer you the legal help you need.
Onglyza is a DPP-4 inhibitor, the type of medication designed to reduce glucose levels and inhibit diabetic complications in adults who have type two diabetes. The FDA (Food and Drug Administration) states that Onglyza users can have a significant risk of developing congestive heart failure. This warning wasn’t on the drug’s label before.
If you took Onglyza and suffered serious complications, or your loved one died from the drug’s side effects, you may have grounds for requesting reimbursement against the manufactures of Onglyza. Know that AstraZeneca is a massive business and has a team of trusted attorneys representing its interests once the company is slapped with lawsuits. That’s why you need skilled class action lawyers in San Francisco to represent you. Contact our firm today at 855-938-0980.
What Is Onglyza?
As a DDP-4 (dipeptidyl peptidase-4) inhibitor, a sort of drug also known as an incretin mimetic, Onglyza has elements that stimulate the pancreas to increase insulin production after the consumer eats a meal. Januvia is just another medication, such as Onglyza, that is used to treat type 2 diabetes. With the rise in insulin levels, the body is able to process glucose (sugars) and be sure they are maintained within the normal range.
FDA approved using Onglyza after reviewing the outcomes of eight clinical trials done by manufacturers AstraZeneca Pharmaceuticals LP. and Bristol-Meyers Squibb Co. The trial contained safety study meant to prove that Onglyza wasn’t associated with any significant risk of cardiovascular disease.
However, recent analyses of the results of a clinical trial on Onglyza accomplished by FDA experts discovered that concerning issues that connected the medicine to heart disease risks. The trial (the SAVOR study), which was sponsored by AstraZeneca, had over 16,000 participants. The participants either had a background or vulnerable to developing cardiovascular disease. A number of them were given Onglyza, and others obtained Placebo.
The researchers tracked the participants’ health advancement for about two years. The results showed a number of the patients who utilized Onglyza were hospitalized for heart failure compared to those who got Placebo. The Onglyza users have a 27 percent increased risk of cardiovascular disease, heart failure, or associated complications.
The outcomes required stricter scrutiny on the drug by the FDA.
Onglyza’s Link to Heart Disease
Cardiovascular disease is one of the top health problems that result in the death of both men and women in the united states. The CDC claims there are almost 610,000 fatalities attributed to cardiovascular disease yearly. If you do the math, that amounts to 1 in every 4 deaths in the USA annually.
It is a type of cardiovascular disease where the body receives an inadequate supply of blood. Thus, less oxygen into its organs, thereby crippling their collective purpose. If not treated, heart failure grows and leads to fatal health issues with deadly consequences.
For people that have type 2 diabetes and are utilizing Onglyza, the connection between their health issues and the drug is alarming. The FDA began an investigation procedure into the medication and how it increases the risk of heart failure; this can be after grown concerns across the United States. The investigation found stressing problems that led to further warnings of heart failure risk linked with the usage of Onglyza in addition to Kombiglyze XR.
Is There A Link Between Onglyza And Pancreatic Cancer?
Because of how Onglyza stimulates the pancreas to release more insulin, that is why the medication has been associated with the consumers confronting a prospective gain in the risk of pancreatitis and pancreatic cancer.
A study was performed in 2013 that focused on how DDP-4 inhibitors influenced the pancreas discovered that participants who had type 2 diabetes and obesity were utilizing Onglyza have a greater probability of having an enlarged pancreas. In addition, they have an elevated risk of having precancerous cellular changes in their pancreas, suggesting a significant probability of developing pancreatic cancer. According to the research, it was also found that tumors (precancerous growths) are prone to require surgical interventions and that the patients using drugs such as Onglyza showed a greater risk of desire pancreatic surgery.
The FDA communicated another drug security awake in March of 2013, saying it had been analyzing findings of a research that indicated the substantial likelihood of pancreatitis and precancerous cellular changes in individuals that were utilizing incretin mimetic to treat their own type 2 diabetes. Among the drugs recorded as incretin mimetics have been Nesina, Januvia, Onglyza, and Byetta.
A later study conducted in 2014 where researchers analyzed data from a significant clinical trial on Onglyza found no indications of pancreatic cancer or the possibility of pancreatitis. They, however, recommended further research to make certain they get conclusive findings that suggest pancreatic safety regarding using incretin mimetics.
Is Onglyza Linked To Thyroid Cancer?
Victoza, an incretin mimetic that shares similarities with Onglyza, was discovered to induce malignant thyroid cancer as well as acute pancreatitis in rodents which were given the drug in”clinically relevant” dosages. Back in June 2011, the FDA issued a security warning saying the risk of thyroid cancer in using Victoza. What’s more, the FDA has received many reports of individuals diagnosed with thyroid cancer after using prescribed incretin mimetics like Byetta (exenatide) and Januvia (sitagliptin).
Has Onglyza Been Recalled?
No recall was announced, and it is unlikely for one to be issued anytime soon. The recalls seem unforthcoming, yet the reality of coronary failure, cancers, and other possibly fatal health issues can’t be overlooked or swept under the carpet. Vioxx was a medication that has been recalled because of causing strokes and heart attacks, among other cardiovascular concerns. The identical fate is due to Onglyza along with other incretin mimetics found to increase the risk of heart failure. But it appears that the only significant measure taken for these drugs with such severe side effects is to demand that the producers incorporate extra safety warnings on their products’ labels. You may encounter a”black box” warning at the top of the drug’s labeling.
Lawsuits Against Onglyza
Drug harm suits are seldom filed as”class action,” whereby a few plaintiffs will signify the others who have instances against a drug company. Instead, you can fill this kind of matter separately.
Back in January 2018, the U.S Judicial Panel on Multidistrict Litigation ordered the”consolidation” of existing lawsuits filed against Kombiglyze and Onglyza from the U.S District Court for the Eastern District of Kentucky. From May 2018, there were around 100 of these cases that shaped consolidated litigation known as the MDL 2809.
Health Issues That Led To Onglyza Lawsuits
Some of the most notable adverse health problems associated with the use of Onglyza comprise:
- Heart failure
- Pancreatitis
- Kidney problems
- Thyroid cancer
- Pancreatic cancer
- Departure
Apart from the severe side effects mentioned above, Onglyza can also be linked to the next moderate to moderate health hazard:
- Headaches
- Urinary tract infections
- Rashes and hives
- Upper respiratory tract infections
Can Lawsuit Against Onglyza Be Filed Despite No FDA Recall?
But this directive has many inquiring why the warning was not included when the product was released ten decades back.
And when this is the present condition of affairs, then it means many of the patients who took Onglyza within the past decade were unaware of the potential health risk.
The law stipulates that drug makers must be responsible for ensuring that the public is informed before they launch a product into the market. It makes them liable for any negative outcomes and functions to protect the public from unnecessary health problems.
And as per the law, patients who took Onglyza and endured heart failure can seek reimbursement because the pharmaceutical companies making the medication don’t provide the public with sufficient safety warnings about this kind of probable outcome.
Get Legal Assistance With A San Francisco Onglyza Lawsuit
In the event that you or a loved one used Onglyza and endured heart failure, hospitalization, or your relative died due to using the medication, the dedicated class action attorneys at our firm are here to assist. We have represented different individuals from throughout the country. Thus, we’ve got a profound understanding o how pharmaceuticals such as Bristol Meyers Squibb and AstraZeneca are anticipated, by law, to make sure physicians and patients are fully conscious of the risk associated with the usage of their drugs. Failure to do this implies that these producers are liable for damages people who use their drugs suffer.
At Class Action Coalition Lawyers, we’ve dealt with cases linked to Onglyza and possess a deep understanding of its flaws. Therefore, we are your very best bet if you would like to face the manufacturers of Onglyza and win. Contact our law offices today at 855-938-0980 for a free consultation, case review, and find out more about your rights.
